Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event
In a case series, two men and one woman aged 46−71 years were described; they developed Candida auris (C. auris) infection during antibacterial treatment with amikacin, cefazolin, ceftazidime, colistin, cotrimoxazole, gentamicin, meropenem, piperacillin/tazobactam or tigecycline [routes, dosages and durations of treatment to reaction onsets not stated; not all outcomes stated].
Case 1: A 46-year-old man, who had been diagnosed with laryngeal carcinoma, was admitted to the ICU following cardiopulmonary arrest during unspecified anaesthesia induction for tumour surgery. During the follow-ups, multiple-drug resistant Acinetobacter baumannii bacteraemia and A. baumannii-Pseudomonas aeruginosa pneumonia was noted. He also underwent urinary, femoral and subclavian catheterisation. Subsequently, he started receiving antibacterial treatment with tigecycline, colistin, meropenem and ceftazidime. On day 66 of hospitalisation, C.auris growth was detected in blood and catheter tip cultures. Thereafter, he was treated with caspofungin. On day 24 of caspofungin treatment, no growth was noted in the cultures. Hence, he was regarded as cured.
Case 2: A 71-year-old woman, who had hypertension, diabetes mellitus, chronic obstructive pulmonary disease and atrial fibrillation, presented to the emergency room with dyspnoea and general condition deterioration, which developed after COVID-19 infection. Subsequently, she was diagnosed with pneumonia and acute renal failure and was admitted to the ICU. Urinary, femoral and jugular catheterisation was performed during hospitalisation. Subsequently, she was diagnosed with methicillin-susceptible Staphylococcus aureus pneumonia and urinary tract infection, which was induced by broad-spectrum beta-lactamase producing Escherichia coli. Therefore, she started receiving antibacterial treatment with cefazolin, amikacin, piperacillin/tazobactam, meropenem and cotrimoxazole [trimethoprim/sulfamethoxazole]. Later, she was intubated due to respiratory failure. On day 16 of ICU admission, C.auris growth was detected in blood and catheter tip cultures. Before the initiation of antifungal treatment, she died [immediate cause of death not stated].
Case 3: A 49-year-old man presented to the emergency room with the complaint of mental fog. Following the diagnosis of subarachnoid haemorrhage, he was admitted to the ICU. Subsequently, he underwent urinary and femoral catheterisation. Thereafter, he developed multidrug-resistant A. baumannii pneumonia and urinary system infection. Hence, he started receiving antibacterial treatment with gentamicin, meropenem and colistin. A urine specimen collected on day 35 of hospitalisation showed a growth of 100 000 CFU/mL C.auris. He was considered to have asymptomatic fungiuria and continued to be followed up at the ICU.